CPhT CONNECT™ Magazine - Volume 5 Issue 2

ce CONTINUING EDUCATION azathioprine Moved from Table 2- to Table 1

Pertuzumab

NIOSH reviewed data from studies provided by the manufacturer and de- termined it is unlikely that pertuzumab poses a carcinogenic, reproductive, or developmental hazard to workers in a healthcare setting and is no longer considered a hazardous drug by NIOSH. NIOSH reviewed data from studies provided by the manufacturer and determined it is unlikely that risperidone poses a carcinogenic, reproductive, or developmental hazard to workers in a healthcare setting and is no longer con- sidered a hazardous drug by NIOSH. NIOSH deleted telavancin from the list based on data from reproductive studies conducted by the manufactur- er regarding its lack of reproductive toxicity.

cabergoline

Moved from Table 3- to Table 2 Moved from Table 2- to Table 1 Moved from Table 2- to Table 1 Moved from Table 3- to Table 2 Moved from Table 3- to Table 2 Moved from Table 3 to Table 2 Moved from Table 2 to Table 1 Moved from Table 3 to Table 2 Moved from Table 2 to Table 1 Moved from Table 2 to Table 1 Moved from Table 3 to Table 2 Moved from Table 3 to Table 2 Moved from Table 2 to Table Moved from Table 1 to Table 2 Moved from Table 1 to Table 2 Moved from Table 1 to Table 2 Moved from Table 3 to Table 2 Moved from Table 2 to Table 1 Moved from Table 3 to Table 2 Moved from Table 3 to Table 2 Moved from Table 3 to Table 2 Moved from Table 3 to Table 2 Moved from Table 3 to Table 2 Moved from Table 2 to Table 1 Moved from Table 3 to Table 2 Moved from Table 3 to Table 2 Moved from Table 3 to Table 2

chloramphenicol

cidofovir

clomiphene clonazepam

Risperidone

colchicine

cyclosporine dutasteride

estrogen-progesterone combinations estrogens, conjugated

Telavancin

finasteride fluconazole ganciclovir letrozole leuprolide megestrol misoprostol

Prior to the release of the NIOSH List of Drugs of Hazardous Drugs in Healthcare Settings, 2024 there were 5 tables of Hazardous Drug Information. The list released in 2024 was reduced from five tables down to two tables. Refer to Table 5 of some of the drugs which were move from which table to their current table.

mycophenolate mofetil

oxytocin

paroxetine

ribavirin

Table 5 Drugs Moved to a Different Table (Excerpts)

temazepam testosterone thalidomide

Drug

Notation

valproate/valproic acid

abiraterone

Moved from Table 1- to Table 2 Moved from Table 3- to Table 2 Moved from Table 1- to Table 2

warfarin

acitretin

ziprasidone

anastrozole

CPhT CONNECT www.cphtconnect.com

45

Made with FlippingBook - PDF hosting